University of British Columbia
Targeted synthetic disease-modifying antirheumatic drugs among mothers with autoimmune disease : pharmacoepidemiologic studies
Abstract
dc:descriptionBackground: Active autoimmune disease during pregnancy increases risk of adverse maternal and neonatal outcomes. Targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) have significantly expanded the management of autoimmune diseases, including rheumatic diseases. As the use of these drugs grows, it is important to understand their patterns of use effects on pregnancy. Objectives: 1) Comprehensively map the literature on the impact of tsDMARDs on pregnancy outcomes in individuals with autoimmune diseases; 2) Characterize patterns of tsDMARD utilization among mothers of childbearing age with autoimmune disease; 3a) Characterize patterns of tsDMARD utilization during the perinatal period; and 3b) Evaluate the association between perinatal tsDMARD exposure and maternal and neonatal outcomes. Methods: For objective 1, I conducted a scoping review including studies that examined tsDMARD exposure in mothers during pregnancy, fathers before conception, and/or fetuses/neonates in-utero. For objective 2, I used population-based administrative health data in British Columbia to identify mothers with autoimmune diseases, summarized demographics of mothers who filled ≥1 tsDMARD prescription, and assessed drug utilization trends between January 1st, 2002 and March 31st, 2022. For objective 3a, I assessed patterns of utilization and discontinuation within the perinatal period. For objective 3b, I evaluated associations between perinatal tsDMARD exposure and maternal and neonatal outcomes. Results: 1) Of 6,712 studies screened, 8 were included. The most frequently reported outcomes were congenital anomaly (n=4) and preterm birth (n=4). 2) Among 17,084 tsDMARD prescriptions filled by mothers diagnosed with autoimmune diseases, tofacitinib and upadacitinib were the most filled drugs. 3a) Among 19 pregnancies with ≥1 tsDMARD dispensation during the perinatal period, 7 (36.8%) pregnancies filled a tsDMARD within 1-year preconception while <5 pregnancies filled a tsDMARD during the first trimester. 3b) Of 22 maternal and neonatal outcomes evaluated (e.g., congenital anomaly, small-for-gestational-age, gestational diabetes), only preterm birth showed a significant association with tsDMARD exposure (unadjusted odds ratio 13.45, 95% confidence interval 2.12-85.21). Conclusions: This thesis provides novel insight into the patterns of use and perinatal impact of tsDMARDs in mothers with autoimmune diseases. Analytical findings contribute to future evidence syntheses to inform clinical guidelines and support family planning and treatment decision-making in patients and providers.
Degree
thesis:*- Name thesis:degree_name
- Master of Science - MSc
- Level thesis:degree_level
- master's
- Discipline thesis:degree_discipline
- Pharmaceutical Sciences
- Grantor dc:publisher
- University of British Columbia
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Cheng, Vienna
- Contributors dc:contributor
-
- De Vera, Mary
Rights
dc:rights- Statement dc:rights
-
- Attribution-NonCommercial-NoDerivatives 4.0 International
- Language dc:language
- eng
Identifiers
dc:identifier.*- Handle dc:identifier
- http://hdl.handle.net/2429/91533